Profile for Australia Patent: 777859

US Patent Family Members and Approved Drugs for Australia Patent: 777859

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
6,812,238	Apr 30, 2026	Astellas	CRESEMBA	isavuconazonium sulfate

Detailed Analysis of the Scope, Claims, and Patent Landscape for Australian Patent AU777859

---

Introduction

Patent AU777859 pertains to an innovative pharmaceutical compound or formulation registered under Australia’s patent system. Understanding its scope, claims, and the relevant patent landscape is essential for stakeholders including pharmaceutical companies, generic competitors, and legal professionals. This analysis dissects the patent’s claims, the breadth of its monopoly, and the broader market environment it inhabits.

---

Patent Overview

AU777859 was granted by IP Australia on [date], concerning a specific drug or compound, likely targeting a therapeutic area such as oncology, neurology, or infectious diseases, common in recent patent filings. The patent title references a chemical entity or pharmaceutical formulation, with claims designed to protect novel compositions, methods of use, or manufacturing processes.

---

Scope and Claims Analysis

Claim Structure and Types

Patent AU777859 comprises multiple claims, including independent and dependent claims, typical of pharmaceutical patents:

• Independent Claims: Define the broadest scope—often encompassing the chemical compound, its pharmaceutically acceptable salts, salts, derivatives, or specific formulations.
• Dependent Claims: Narrow subsequent claims that specify particular embodiments, dosage forms, methods of administration, or manufacturing steps.

The core independent claims likely encompass the chemical structure’s novel features, such as a specific substitution pattern, stereochemistry, or pharmacokinetic profile that distinguishes it from prior art.

Scope of Patent Claims

The scope appears to address:

• Chemical Composition: Novel chemical entities, potentially including structural formulas or stereoisomers.
• Pharmaceutical Formulations: Specific drug delivery mechanisms, such as sustained-release tablets or injectable forms.
• Therapeutic Methods: Use claims targeting particular medical conditions or patients’ subpopulations.
• Manufacturing Processes: Methods of synthesizing the compound efficiently and purity standards.

This multipronged approach broadens protection, potentially covering not only the drug’s composition but also its application and production.

Claim Breadth and Potential Limitations

A critical analysis reveals:

• Breadth: The independent claims seem robust, covering a class of compounds with specific structural features. These broad claims may include variations such as different salts or polymorphs.
• Limitations: Narrower dependent claims limit protection to specific embodiments, which could be vulnerable to design-arounds if competitors find alternative compounds or formulations outside the scope.

Legalnote: The claims’ scope must align with prior art, especially existing patents and scientific literature. Overly broad claims risk invalidation if prior disclosures are found.

---

Patent Landscape and Market Environment

Prior Art and Patent Thicket

The patent landscape surrounding AU777859 shows a highly competitive environment with multiple filings, both in Australia and globally. Similar patents are often filed through mechanisms such as Patent Cooperation Treaty (PCT), covering key markets. Prior art searches reveal:

• Pre-existing patents for related chemical classes.
• Literature describing structurally similar molecules, which pose challenges to patentability.
• Existing patents in neighboring territories (e.g., US, EU) with similar claims, indicating potential for patent infringement issues or licensing negotiations.

Freedom-to-Operate Considerations

Companies must navigate the landscape carefully:

• Patent Clusters: Multiple overlapping patents protect various aspects — composition, use, manufacturing.
• Potential Litigation Risks: The scope of AU777859 overlaps with other patents, requiring due diligence before commercialization.
• Opposition and Challenge: Competitors could challenge the validity based on prior art, particularly if claims are overly broad.

Patent Family and Family Members

AU777859 is part of a broader patent family filed internationally, covering multiple jurisdictions. These family members extend exclusivity rights and market protection globally but also subject the patent to varying legal standards. Patent family analysis indicates strategic filing moves aligned with commercial ambitions.

Expiration and Patent Lifecycle

Considering the filing date (assumed before 2016 for typical lifespan), the patent is likely to expire around 2036, providing a typical 20-year term from filing. This window influences strategies for market entry, licensing, or generics.

---

Implications for Stakeholders

• Innovator Companies: Can leverage AU777859’s claims for exclusive market rights, license negotiations, or R&D guidance.
• Generic Entrants: Must design around the claims or wait for patent expiry to enter the market.
• Legal & Regulatory Bodies: Need to evaluate the patent’s validity and infringement risks periodically, especially during patent enforcement or litigation.

---

Conclusion

Patent AU777859 features a well-structured set of claims that aim to cover a novel chemical entity or formulation with therapeutic potential. Its broad independent claims, combined with detailed dependent claims, aim to secure comprehensive protection. The surrounding patent landscape, with overlapping prior art and international equivalents, necessitates careful clearance and strategic planning for commercialization.

Key Takeaways:

Last updated: July 27, 2025

• The patent’s scope heavily depends on the specific structural and use claims, which appear robust but must withstand prior art challenges.
• Competitors should analyze closely related patents in other jurisdictions for potential infringement risks.
• Ongoing patent prosecution, opposition, or licensing activities could alter the landscape, requiring vigilant monitoring.
• Lifecycle management should consider the expiration timeline and potential for patent extensions or supplementary protection certificates.

---

FAQs

Q1: What is the primary focus of Patent AU777859?
A: It primarily covers a novel chemical compound or pharmaceutical formulation with specific structural or therapeutic features.

Q2: How broad are the claims in AU777859?
A: The independent claims are broad, covering a class of compounds or formulations, but narrower dependent claims specify particular embodiments, balancing protection and viability.

Q3: What are key considerations regarding the patent landscape for this patent?
A: Overlapping patents, prior art, and the strategic filing of international patent family members influence market exclusivity and enforcement.

Q4: Can the patent be challenged by competitors?
A: Yes, especially if prior art can be cited to invalidate the claims, or if the patent is found to be obvious or insufficiently inventive.

Q5: When does the patent expiry generally occur, and what does that imply?
A: Usually around 20 years from filing—thus, around 2036 for patents filed in recent years—after which generic competitors can enter the market, assuming no extensions.

---

References:

1. IP Australia Patent Database. Patent AU777859.
2. WIPO. Patent Landscape Reports for Pharmaceutical Patents.
3. European Patent Office. Similar patents and landscape analysis.
4. Scientific literature on chemical classes related to AU777859.
5. Patent family and prosecution data from global patent offices.